微芯生物：2025年营收9.10亿元，净利润扭亏为盈

Core Viewpoint - Microchip Biotech announced a significant financial turnaround for the fiscal year 2025, achieving a total revenue of 910 million yuan, representing a year-on-year growth of 38.24% [1] Financial Performance - The company reported a total profit of 50.84 million yuan, compared to a loss of 96.71 million yuan in the same period last year [1] - The net profit attributable to shareholders reached 51.08 million yuan, a recovery from a net loss of 115 million yuan in the previous year [1] Product Sales - Sales revenue from the product Siglecatin increased by approximately 122% year-on-year [1] - Sales revenue from the product Sidabamine grew by around 16% year-on-year [1] Data Verification - The financial data provided is preliminary and unaudited, with the final figures to be confirmed in the 2025 annual report [1]